You're watching...
Auxilium Pharmaceuticals CEO Adrian Adams on how the Supreme Court ruling on health care could affect the pharmaceutical sector.
Also in this playlist...
Auto-advance: ON
Auto-advance
This transcript is automatically generated
Out of business -- standing by to see how the supreme court's ruling will impact these companies.
And of course you may -- the stocks you may want to own the stocks and these are companies that spend years and millions of dollars.
Researching and developing drugs and therapies to fix all our ailments Adrian Adams is one of those people he is president and CEO of Auxilium Pharmaceuticals.
He's joining us now in -- Fox Business exclusive.
Your company has a drug working on something very specific penile curvature now.
Regardless of what happens with the health care law argue -- yet or are you ready to embrace what ever the decision and it's.
Well I think part of being these specialty pharmaceutical industry is that that we can focus on areas.
-- -- -- need so.
Who we believe -- we have a strong interest in what's gonna come out on Thursday but we do not think it's gonna impact significantly.
All business and the reason for that is that we focus our attention -- it.
Developments live and commercial -- on areas of high unmet -- OK so we should also mention by the way this is a publicly traded company that stock up 33%.
Over the past year.
You've done very well by your shareholders so you're here to say that no matter how this goes down because it's a big difference if say for example the whole thing -- struck down -- that's more than thirty million people who won't then be covered under that particular health care law.
Who could not affect the usage or I guess the demand for your product.
I think potentially across the industry a different pharmaceutical companies have different business models.
And the fact that we had Auxilium I think focus predominately -- a pile -- like pearl is deceased.
Like duke -- contraction next that we -- with some change like that and we can -- to change very yeah very efficiently.
Is there one way you'd like to see this room now.
I don't really have a not an opinion on that in the end I think the pharmaceutical -- -- have many challenges over the course.
But the years I think we have to adapt to whatever comes out about so so we will -- And you -- -- you've been the CEO of your logic she'd been at Sepracor you've got a thirty year history of working with these companies.
And -- was I right when I said that you've got people working for sometimes more than a decade to develop certain drugs.
You put in huge amount of investment does it worry you that that somehow that investment might be -- somehow.
If this health care -- put into place or what it helped that the demand would go.
Of course it wasn't so it worries me about -- option to correct that's.
Develop and drug some particulars of on that -- can take many many years and we have people who working diligently to to do so of course on.
Were concerned about about books.
When we step back on aspects like this we have to full personal business model we believe that all business model of developing drugs for unmet need this woman to -- -- not test of time as you go through the process of seeking approval for certain drugs.
Will any of that change no matter what happens or do you still go to the same FDA approval process which can be onerous depending on what you're putting out there.
Absolutely Catholic the FDA processes relatively well defined and I think we have meetings with the F scale -- on what basis -- -- relates to drug development.
Under -- timeline so well let out some we adopt without them we focus on the -- and to bring drugs to to the market -- from the UK obviously we hear the accent does this American process confound you for do you understand it.
I think I understand that clearly I think having their what's in the industry for quite some considerable time I think with a number of confidence I've learned to adapt to -- to change Africa.
Nothing really surprises -- fifth in the mall Sakhalin thing is to try control.
Vols things that I can control and a -- Auxilium I can control execution and making sure that we can bring drugs to market.
The make a difference -- -- left what you -- patrons.
I'm -- disease yes.
Which is penile curvature and you know it's not often I get to say that on the air but being a urologist daughter I'm very comfortable saying that's a big effect thank you so much thank you so much you're doing good work Adrian Adams president and CEO of Auxilium Pharmaceuticals we'll see you next time.
